EXACT Therapeutics
EXACT Therapeutics AS is a Norwegian clinical-stage biopharmaceutical company developing ultrasound-mediated drug delivery platforms for targeted therapeutic enhancement. The company develops Acoustic Cluster Therapy (ACT), a proprietary technology utilizing microbubble-microdroplet clusters activated by ultrasound to increase drug permeability in targeted diseased tissue. Revenue is generated through strategic research collaborations, grant funding, licensing agreements, and development capital raised ahead of commercialization. Core end markets encompass clinical oncology centers, GI oncology units, central nervous system treatment specialists, and global biopharmaceutical partners. EXACT Therapeutics holds a pioneer position in ultrasound-assisted targeted drug delivery and nanomedicine. The company is headquartered in Oslo, Norway, and its shares trade on Euronext Growth Oslo.
2 of the funds FundTelligence covers report a position in EXACT Therapeutics.
- Sector
- Health Care
- Country
- Norway
- Funds holding it
- 2
Funds holding EXACT Therapeutics
- Danske Invest Norge Vekst — Danske Invest · 0.08 % (full portfolio disclosed, September 2026)
- Nordea Avkastning — Nordea Funds · 0.01 % (full portfolio disclosed, September 2026)